copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Home | GSK US Press releases October 10 2024 GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024 October 09 2024 Statement: Zantac (ranitidine) litigation – settlement agreements reached
Products - GSK US Products Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together Below you can find the full A-Z list of our products available in the United States
Careers | GSK US Ahead Together At GSK, we unite science, technology and talent to get ahead of disease together We aim to positively impact the health of 2 5 billion people by the end of the decade, as a successful, growing company where people can thrive
Contact us - GSK Contact us online at GSK for You RRC - a reimbursement support program that helps patients and healthcare professionals in the US with coverage, coding and reimbursement issues for certain GSK products
At a glance | GSK US At a glance Getting Ahead Together means preventing disease as well as treating it Globally, our portfolio spans vaccines, specialty and general medicines, with R D focused on science of the immune system, human genetics and advanced technologies
Search jobs - GSK US GSK plc Registered in England and Wales No 3888792 Registered office: 79 New Oxford Street, London United Kingdom WC1A 1DG GSK websites GSK Global website Locations selector Global Behind the science
Press releases | GSK US US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
GSK announces cap of $35 per month on U. S. patient out-of-pocket costs . . . GSK today announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease (COPD) medicines,* the most prescribed portfolio of inhalers in the U S GSK is taking this action as part of its longstanding commitment to improving access to respiratory
Charitable grants - GSK US GSK IMPACT Awards support and reward small- to mid-sized nonprofit organizations in Greater Philadelphia and in the Triangle Region of North Carolina that are improving community health through the social determinants of health